Compare

Accustem Sciences Inc. vs Semnur Pharmaceuticals, Inc. vs Aspire-Lakewood Holdings, Inc. vs Alzamend Neuro, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAccustem Sciences Inc.
ACUT
Semnur Pharmaceuticals, Inc.
SMNR
Aspire-Lakewood Holdings, Inc.
ASBP
Alzamend Neuro, Inc.
ALZN
Year ended2025-12-312025-12-312025-12-312026-04-30
Revenuen/an/a$6.2Kn/a
Revenue growth (YoY)n/an/an/an/a
Gross marginn/an/a-1.9%n/a
Operating marginn/an/an/mn/a
Net marginn/an/an/mn/a
Net income-$1.76M-$160.42M-$24.48M-$8.77M
EPS (Diluted)-$0.12-$0.78-$16.38-$2.63
Operating cash flow-$850.4K-$5.87M-$4.92M-$8.07M
Free cash flown/an/an/an/a
Cash & equivalentsn/a$20.0Kn/a$710.7K
Total assets$1.55M$1.35M$1.31M$2.08M
Total liabilities$4.95M$22.10M$7.69M$1.35M
Shareholders' equity-$3.40M-$20.75M-$6.38M$733.2K
Return on year-end equityn/an/an/an/m
Shares outstanding16.07M230.21M3.53M4.26M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAccustem Sciences Inc.Semnur Pharmaceuticals, Inc.Aspire-Lakewood Holdings, Inc.Alzamend Neuro, Inc.
Latestn/an/a$6.2K
Ended 2025-12-31
n/a
1 year earliern/an/an/an/a
2 years earliern/an/an/an/a
3 years earliern/an/an/an/a
4 years earliern/an/an/an/a